PURPOSE: To determine changes in regional airflow obstruction over time in the lungs of patients with asthma, as demonstrated with hyperpolarized helium 3 ((3)He) magnetic resonance (MR) imaging, and to assess correlations with disease severity and use of asthma medications. MATERIALS AND METHODS: Institutional review board approval and written informed consent were obtained for this HIPAA-compliant study. Use of (3)He was approved by the U.S. Food and Drug Administration. Forty-three patients underwent 103 MR imaging studies in total; 26 were imaged twice within 42-82 minutes (same day), and 17 were imaged on 3 days between 1 and 476 days (multiday). Each day, spirometry was performed, disease severity was determined, and the use of asthma medications was recorded. Images were reviewed in a pairwise fashion to determine total ventilation defect number, defects in same location between imaging studies, and size. Parametric and nonparametric statistical methods were used. RESULTS: For the same-day examinations, the mean number of defects per image section was similar at baseline and repeat imaging (1.8 +/- 1.9 [standard deviation] vs 1.6 +/- 1.9, respectively; P = .15), with 75% of defects remaining in the same location and 71% of these not changing size. For the multiday examinations, the mean number of defects per section was higher for study 2 (2.4 +/- 1.5) than study 1 (1.7 +/- 0.9, P = .02), was lower for study 3 (1.5 +/- 1.1) than for study 2 (P < .01), and was similar for studies 1 and 3 (P = .56). Time between examinations was not associated with change in mean number of defects per section (median intrasubject correlation [r(m)] = 0.01, P = .64) or change in spirometric values (range of r(m) values: -0.56 to -0.31; range of P values: .09-.71). Defects in the same location decreased with time (r(m) = -0.83, P < .01), with 67% persisting between studies 1 and 2 (median interval, 31 days), 43% persisting between studies 2 and 3 (median interval, 41 days), and 38% persisting between studies 1 and 3 (median interval, 85 days); 46%-58% of defects remained unchanged in size. These trends were the same regardless of disease severity or medication use. CONCLUSION: In asthma, focal airflow impediment within the lungs can be markedly persistent over time, regardless of disease severity or treatment.
PURPOSE: To determine changes in regional airflow obstruction over time in the lungs of patients with asthma, as demonstrated with hyperpolarized helium 3 ((3)He) magnetic resonance (MR) imaging, and to assess correlations with disease severity and use of asthma medications. MATERIALS AND METHODS: Institutional review board approval and written informed consent were obtained for this HIPAA-compliant study. Use of (3)He was approved by the U.S. Food and Drug Administration. Forty-three patients underwent 103 MR imaging studies in total; 26 were imaged twice within 42-82 minutes (same day), and 17 were imaged on 3 days between 1 and 476 days (multiday). Each day, spirometry was performed, disease severity was determined, and the use of asthma medications was recorded. Images were reviewed in a pairwise fashion to determine total ventilation defect number, defects in same location between imaging studies, and size. Parametric and nonparametric statistical methods were used. RESULTS: For the same-day examinations, the mean number of defects per image section was similar at baseline and repeat imaging (1.8 +/- 1.9 [standard deviation] vs 1.6 +/- 1.9, respectively; P = .15), with 75% of defects remaining in the same location and 71% of these not changing size. For the multiday examinations, the mean number of defects per section was higher for study 2 (2.4 +/- 1.5) than study 1 (1.7 +/- 0.9, P = .02), was lower for study 3 (1.5 +/- 1.1) than for study 2 (P < .01), and was similar for studies 1 and 3 (P = .56). Time between examinations was not associated with change in mean number of defects per section (median intrasubject correlation [r(m)] = 0.01, P = .64) or change in spirometric values (range of r(m) values: -0.56 to -0.31; range of P values: .09-.71). Defects in the same location decreased with time (r(m) = -0.83, P < .01), with 67% persisting between studies 1 and 2 (median interval, 31 days), 43% persisting between studies 2 and 3 (median interval, 41 days), and 38% persisting between studies 1 and 3 (median interval, 85 days); 46%-58% of defects remained unchanged in size. These trends were the same regardless of disease severity or medication use. CONCLUSION: In asthma, focal airflow impediment within the lungs can be markedly persistent over time, regardless of disease severity or treatment.
Authors: Mario Castro; Sean B Fain; Eric A Hoffman; David S Gierada; Serpil C Erzurum; Sally Wenzel Journal: J Allergy Clin Immunol Date: 2011-06-02 Impact factor: 10.793
Authors: Sanghun Choi; Eric A Hoffman; Sally E Wenzel; Merryn H Tawhai; Youbing Yin; Mario Castro; Ching-Long Lin Journal: J Appl Physiol (1985) Date: 2013-06-06
Authors: Mats W Johansson; Stanley J Kruger; Mark L Schiebler; Michael D Evans; Ronald L Sorkness; Loren C Denlinger; William W Busse; Nizar N Jarjour; Robert R Montgomery; Deane F Mosher; Sean B Fain Journal: Am J Respir Crit Care Med Date: 2013-07-15 Impact factor: 21.405
Authors: Nanae Tsuchiya; Mark L Schiebler; Michael D Evans; Robert V Cadman; Ronald L Sorkness; Robert F Lemanske; Daniel J Jackson; Nizar N Jarjour; Loren C Denlinger; Sean B Fain Journal: Pediatr Radiol Date: 2020-01-24
Authors: Rui Carlos Sá; Amran K Asadi; Rebecca J Theilmann; Susan R Hopkins; G Kim Prisk; Chantal Darquenne Journal: J Appl Physiol (1985) Date: 2014-02-06
Authors: Paolo B Dominelli; Yannick Molgat-Seon; Glen E Foster; Giulio S Dominelli; Hans C Haverkamp; William R Henderson; A William Sheel Journal: Respir Physiol Neurobiol Date: 2015-09-18 Impact factor: 1.931